Xeltis CEO, Laurent Grandidier, discusses how the company secured significant Series B funding in spite of the increasingly tough medtech financial environment in European CEO magazine. “A truly innovative and scalable technology that may substantially benefit the healthcare system, the right long-term investors and an executive team delivering on expected value creation are key success factors of our venture,” explained Grandidier. Trends in medtech financing have been reviewed this week by Evaluate, the healthcare market intelligence group, reporting on venture capitalists consistently moving away from early stage medtech start-ups to increasingly focus on large investment rounds for more established companies.
